<p>紐約，2026 年 1 月 20 日（全球新聞稿）——Psyence Biomedical Ltd.（納斯達克：PBM）（“Psyence BioMed” 或 “公司”）今天宣佈，決定推遲之前宣佈的反向股票拆分的生效日期。</p>
<p>如之前所披露，公司董事會批准了 1 比 6.25 的反向股票拆分，計劃於 2026 年 1 月 20 日市場開盤時生效。經過進一步的內部考慮，公司決定將反向股票拆分的生效日期推遲至更晚的時間。</p>
<p>公司將在確定反向股票拆分的新生效日期之前發佈後續新聞稿，並向納斯達克提交任何必要的通知。在此之前，公司普通股將繼續以未調整拆分的方式在納斯達克資本市場交易，股票代碼為 “PBM”，並保持當前的 CUSIP 74449F308。</p>
<p>董事會保留決定反向股票拆分是否以及何時生效的權力。</p>
<p><strong>關於 Psyence BioMed</strong></p>
<p>Psyence Biomedical Ltd.（納斯達克：PBM）是少數幾家專注於迷幻藥物治療的多資產、垂直整合的生物製藥公司之一。它是第一家專注於開發自然來源（非合成）的裸蓋菇素和伊波卡因基礎的迷幻藥物的生命科學生物技術公司，並在納斯達克上市。我們致力於解決未滿足的心理健康需求。我們承諾採用基於證據的方法，開發安全、有效且獲得 FDA 批准的自然來源迷幻治療，針對廣泛的心理健康障礙。</p>
<p><strong>Psyence Biomedical Ltd. 聯繫信息</strong></p>
<p>電子郵件：ir@psyencebiomed.com</p>
<p>媒體諮詢：media@psyencebiomed.com</p>
<p>一般信息：info@psyencebiomed.com</p>
<p><strong>投資者聯繫：</strong></p>
<p>Michael Kydd</p>
<p>投資者關係顧問</p>
<p>michael@psyencebiomed.com</p>
<p><strong>前瞻性聲明</strong></p>
<p>本通訊包含 1995 年《私人證券訴訟改革法案》所定義的 “前瞻性聲明”。此類聲明包括但不限於關於未來財務和運營結果、我們的計劃、目標、期望和意圖的聲明，涉及未來的運營、產品和服務；以及其他用 “可能導致”、“預期”、“將繼續”、“預計”、“估計”、“相信”、“打算”、“計劃”、“預測”、“展望” 或類似含義的詞語標識的聲明。</p>
<p>本通訊中的前瞻性聲明包括關於之前宣佈的反向股票拆分的潛在未來有效性、該有效性的時間（如有）以及公司決定是否以及何時進行反向股票拆分的意圖。這些聲明基於當前的假設和期望，包括公司可能選擇為反向股票拆分設定新的生效日期，以及公司將繼續滿足納斯達克的持續上市標準。這些假設可能被證明是錯誤的。不能保證公司能夠保持符合納斯達克的持續上市要求。存在許多風險和不確定性，可能導致實際結果或表現與這些前瞻性聲明所表達或暗示的結果有重大不同。</p>
<p>這些風險和不確定性包括但不限於：（i）在決定是否實施或實施反向股票拆分時的延遲或挑戰；（ii）公司維持符合納斯達克持續上市標準的能力；（iii）無論反向股票拆分是否最終實施，公司股價可能的波動；（iv）監管、競爭和經濟環境的變化；（v）與公司發展計劃和臨牀試驗相關的風險；以及（vi）與公司對股票合併的公司授權相關的風險，包括對授權股票合併的股東決議的有效性、解釋或充分性的質疑或訴訟的可能性。上述因素的清單並不詳盡。您應仔細考慮上述因素以及公司最終招股説明書（文件編號：333-298285）中 “風險因素” 部分描述的其他風險和不確定性，該招股説明書於 2025 年 11 月 3 日提交給證券交易委員會（“SEC”），以及 Psyence BioMed 不時向 SEC 提交的其他文件。</p>
<p>這些文件識別並解決了可能導致實際事件和結果與前瞻性聲明中包含的內容有重大不同的其他重要風險和不確定性。實際結果和未來事件可能與這些聲明中預期的有重大不同。本通訊中的任何內容均不應被視為任何人對前瞻性聲明所述內容將會實現的陳述，或對這些前瞻性聲明所設想的任何結果將會實現的陳述。您不應對前瞻性聲明過度依賴，這些聲明僅在作出時有效。除法律要求外，Psyence BioMed 不打算更新這些前瞻性聲明。</p>
<p>公司不對其擬議產品做出任何醫療、治療或健康益處的聲明。美國食品藥品監督管理局、加拿大衞生部或其他類似監管機構尚未評估關於迷幻蘑菇、迷幻蘑菇類似物或其他迷幻化合物或營養保健產品的聲明。這些產品的有效性尚未通過授權的臨牀研究確認。無法保證使用迷幻蘑菇、迷幻蘑菇類似物或其他迷幻化合物或營養保健品能夠診斷、治療、治癒或預防任何疾病或狀況。需要進行嚴格的科學研究和臨牀試驗。公司的產品候選者屬於研究性質，尚未獲得任何監管機構的批准用於治療任何疾病或狀況，臨牀結果（如有）可能無法代表未來的結果。任何關於潛在產品的質量、一致性、有效性和安全性的引用並不意味着公司已在臨牀試驗中驗證這些內容，或公司將完成這些試驗。如果公司無法獲得商業化其業務所需的批准或研究，可能會對公司的業績和運營產生重大不利影響。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU9EWXlPQ00zTXpjd01EZzRJekl5T0RVNU1UYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU9EWXlPQ00zTXpjd01EZzRJekl5T0RVNU1UYz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MWE2NWY3YzUtMjgyYy00NTgwLTg5N2QtY2FhYTczMmNmMjBkLTEyOTc0NjctMjAyNi0wMS0yMC1lbg==/tiny/Psyence-Biomedical-Ltd-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MWE2NWY3YzUtMjgyYy00NTgwLTg5N2QtY2FhYTczMmNmMjBkLTEyOTc0NjctMjAyNi0wMS0yMC1lbg==/tiny/Psyence-Biomedical-Ltd-.png"/></p>

<p>Psyence Biomedical Ltd. 已推遲其之前宣佈的 1 比 6.25 的反向股票拆分的生效日期，原定於 2026 年 1 月 20 日。此決定是在進一步內部考慮後做出的，公司將發佈新的新聞稿，公佈修訂後的生效日期。在此之前，股票將繼續在納斯達克以 "PBM" 的代碼交易，且不作調整。董事會保留拆分時機的決定權</p>

<p>NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced that it has decided to postpone the previously announced effective date of its reverse stock split of its issued and outstanding shares of common stock.</p>
<div class="lb-trans"><p>紐約，2026 年 1 月 20 日（全球新聞稿）——Psyence Biomedical Ltd.（納斯達克：PBM）（“Psyence BioMed” 或 “公司”）今天宣佈，決定推遲之前宣佈的反向股票拆分的生效日期。</p>
</div><p>As previously disclosed, the Company’s Board of Directors approved a reverse stock split at a ratio of 1-for-6.25, which was intended to become effective at the opening of the market on January 20, 2026. Following further internal consideration, the Company has elected to delay the effectiveness of the reverse stock split to a later date.</p>
<div class="lb-trans"><p>如之前所披露，公司董事會批准了 1 比 6.25 的反向股票拆分，計劃於 2026 年 1 月 20 日市場開盤時生效。經過進一步的內部考慮，公司決定將反向股票拆分的生效日期推遲至更晚的時間。</p>
</div><p>The Company will issue a subsequent press release and file any required notifications with Nasdaq prior to establishing a new effective date for the reverse stock split. Until such time, the Company’s common stock will continue to trade on the Nasdaq Capital Market on a split-unadjusted basis under the ticker symbol &#34;PBM&#34; and under its current CUSIP 74449F308.</p>
<div class="lb-trans"><p>公司將在確定反向股票拆分的新生效日期之前發佈後續新聞稿，並向納斯達克提交任何必要的通知。在此之前，公司普通股將繼續以未調整拆分的方式在納斯達克資本市場交易，股票代碼為 “PBM”，並保持當前的 CUSIP 74449F308。</p>
</div><p>The Board of Directors retains the discretion to determine if and when the reverse stock split will be effected.</p>
<div class="lb-trans"><p>董事會保留決定反向股票拆分是否以及何時生效的權力。</p>
</div><p><strong>About Psyence BioMed</strong></p>
<div class="lb-trans"><p><strong>關於 Psyence BioMed</strong></p>
</div><p>Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs. We are committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.</p>
<div class="lb-trans"><p>Psyence Biomedical Ltd.（納斯達克：PBM）是少數幾家專注於迷幻藥物治療的多資產、垂直整合的生物製藥公司之一。它是第一家專注於開發自然來源（非合成）的裸蓋菇素和伊波卡因基礎的迷幻藥物的生命科學生物技術公司，並在納斯達克上市。我們致力於解決未滿足的心理健康需求。我們承諾採用基於證據的方法，開發安全、有效且獲得 FDA 批准的自然來源迷幻治療，針對廣泛的心理健康障礙。</p>
</div><p><strong>Contact Information for Psyence Biomedical Ltd.</strong></p>
<div class="lb-trans"><p><strong>Psyence Biomedical Ltd. 聯繫信息</strong></p>
</div><p>Email: ir@psyencebiomed.com</p>
<div class="lb-trans"><p>電子郵件：ir@psyencebiomed.com</p>
</div><p>Media Inquiries: media@psyencebiomed.com</p>
<div class="lb-trans"><p>媒體諮詢：media@psyencebiomed.com</p>
</div><p>General Information: info@psyencebiomed.com</p>
<div class="lb-trans"><p>一般信息：info@psyencebiomed.com</p>
</div><p><strong>Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>投資者聯繫：</strong></p>
</div><p>Michael Kydd</p>
<div class="lb-trans"><p>Michael Kydd</p>
</div><p>Investor Relations Advisor</p>
<div class="lb-trans"><p>投資者關係顧問</p>
</div><p>michael@psyencebiomed.com</p>
<div class="lb-trans"><p>michael@psyencebiomed.com</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning.</p>
<div class="lb-trans"><p>本通訊包含 1995 年《私人證券訴訟改革法案》所定義的 “前瞻性聲明”。此類聲明包括但不限於關於未來財務和運營結果、我們的計劃、目標、期望和意圖的聲明，涉及未來的運營、產品和服務；以及其他用 “可能導致”、“預期”、“將繼續”、“預計”、“估計”、“相信”、“打算”、“計劃”、“預測”、“展望” 或類似含義的詞語標識的聲明。</p>
</div><p>Forward-looking statements in this communication include statements regarding the potential future effectiveness of the previously announced reverse stock split, the timing (if any) of such effectiveness, and the Company’s intention to determine whether and when to proceed with the reverse stock split. These statements are based on current assumptions and expectations, including that the Company may elect to establish a new effective date for the reverse stock split, and that the Company will continue to meet Nasdaq’s ongoing listing standards. These assumptions may prove incorrect. There can be no assurance that the Company will be able to maintain compliance with Nasdaq’s continued listing requirements. There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.</p>
<div class="lb-trans"><p>本通訊中的前瞻性聲明包括關於之前宣佈的反向股票拆分的潛在未來有效性、該有效性的時間（如有）以及公司決定是否以及何時進行反向股票拆分的意圖。這些聲明基於當前的假設和期望，包括公司可能選擇為反向股票拆分設定新的生效日期，以及公司將繼續滿足納斯達克的持續上市標準。這些假設可能被證明是錯誤的。不能保證公司能夠保持符合納斯達克的持續上市要求。存在許多風險和不確定性，可能導致實際結果或表現與這些前瞻性聲明所表達或暗示的結果有重大不同。</p>
</div><p>These risks and uncertainties include, among others: (i) delays or challenges in determining whether to effect or in effecting the reverse stock split; (ii) the Company’s ability to maintain compliance with Nasdaq’s continued listing standards; (iii) potential volatility in the Company’s share price whether or not a reverse stock split is ultimately effected; (iv) changes in the regulatory, competitive, and economic landscape; (v) risks associated with the Company’s development plans and clinical trials; and (vi) risks related to the Company’s corporate authorizations for the share consolidation, including the possibility of claims or proceedings challenging the validity, interpretation or sufficiency of the shareholder resolutions authorizing the share consolidation. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-298285) filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025 and other documents filed by Psyence BioMed from time to time with the SEC.</p>
<div class="lb-trans"><p>這些風險和不確定性包括但不限於：（i）在決定是否實施或實施反向股票拆分時的延遲或挑戰；（ii）公司維持符合納斯達克持續上市標準的能力；（iii）無論反向股票拆分是否最終實施，公司股價可能的波動；（iv）監管、競爭和經濟環境的變化；（v）與公司發展計劃和臨牀試驗相關的風險；以及（vi）與公司對股票合併的公司授權相關的風險，包括對授權股票合併的股東決議的有效性、解釋或充分性的質疑或訴訟的可能性。上述因素的清單並不詳盡。您應仔細考慮上述因素以及公司最終招股説明書（文件編號：333-298285）中 “風險因素” 部分描述的其他風險和不確定性，該招股説明書於 2025 年 11 月 3 日提交給證券交易委員會（“SEC”），以及 Psyence BioMed 不時向 SEC 提交的其他文件。</p>
</div><p>These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements.</p>
<div class="lb-trans"><p>這些文件識別並解決了可能導致實際事件和結果與前瞻性聲明中包含的內容有重大不同的其他重要風險和不確定性。實際結果和未來事件可能與這些聲明中預期的有重大不同。本通訊中的任何內容均不應被視為任何人對前瞻性聲明所述內容將會實現的陳述，或對這些前瞻性聲明所設想的任何結果將會實現的陳述。您不應對前瞻性聲明過度依賴，這些聲明僅在作出時有效。除法律要求外，Psyence BioMed 不打算更新這些前瞻性聲明。</p>
</div><p>The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company’s product candidates are investigational and have not been approved by any regulatory authority for use in the treatment of any disease or condition, and clinical results (if any) may not be indicative of future results. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.</p>
<div class="lb-trans"><p>公司不對其擬議產品做出任何醫療、治療或健康益處的聲明。美國食品藥品監督管理局、加拿大衞生部或其他類似監管機構尚未評估關於迷幻蘑菇、迷幻蘑菇類似物或其他迷幻化合物或營養保健產品的聲明。這些產品的有效性尚未通過授權的臨牀研究確認。無法保證使用迷幻蘑菇、迷幻蘑菇類似物或其他迷幻化合物或營養保健品能夠診斷、治療、治癒或預防任何疾病或狀況。需要進行嚴格的科學研究和臨牀試驗。公司的產品候選者屬於研究性質，尚未獲得任何監管機構的批准用於治療任何疾病或狀況，臨牀結果（如有）可能無法代表未來的結果。任何關於潛在產品的質量、一致性、有效性和安全性的引用並不意味着公司已在臨牀試驗中驗證這些內容，或公司將完成這些試驗。如果公司無法獲得商業化其業務所需的批准或研究，可能會對公司的業績和運營產生重大不利影響。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU9EWXlPQ00zTXpjd01EZzRJekl5T0RVNU1UYz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYyODYyOCM3MzcwMDg4IzIyODU5MTc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MWE2NWY3YzUtMjgyYy00NTgwLTg5N2QtY2FhYTczMmNmMjBkLTEyOTc0NjctMjAyNi0wMS0yMC1lbg==/tiny/Psyence-Biomedical-Ltd-.png" alt="" original-src="https://ml.globenewswire.com/media/MWE2NWY3YzUtMjgyYy00NTgwLTg5N2QtY2FhYTczMmNmMjBkLTEyOTc0NjctMjAyNi0wMS0yMC1lbg==/tiny/Psyence-Biomedical-Ltd-.png"/></p>

Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date | PBM Stock News

StockTitan

美國制藥 ETF - iShares

醫療業 ETF - Vanguard

紐交所高增長板生物技術指數 ETF - First Trust

生物科技 ETF - VanEck Vectors

2 倍做多納斯達克生物技術 ETF - ProShares

醫療業 ETF - SPDR

納斯達克生物科技指數 ETF - iShares Nasdaq

基因改革 ETF - ARK

醫藥突破 ETF - ALPS

動態生物技術與基因組 ETF - Invesco

Psyence Biomedical

標普生物技術 ETF - SPDR

Psyence BioMed 宣佈推遲之前宣佈的反向股票拆分生效日期 | PBM 股票新聞